ProMIS Neurosciences Inc. is a biotechnology company focused on developing innovative therapeutic solutions for neurodegenerative diseases, particularly those associated with misfolded proteins such as Alzheimer’s disease
The company utilizes its proprietary protein misfolding technology to create novel antibodies that target specific disease-causing proteins, aiming to improve outcomes for patients suffering from these debilitating conditions. Through its research efforts, ProMIS seeks to advance the understanding of neurodegeneration and provide effective treatments that may alter the course of these diseases.
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&P 500 also rose, gaining, 0.80% to 5,164.30.
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling over 100 points on Tuesday. The Dow traded down 0.39% to 34,330.87 while the NASDAQ rose 0.24% to 13,530.50. The S&P 500, also fell, dropping, 0.11% to 4,394.78.
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQRARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
Gainers Axcella Health Inc. (NASDAQAXLA) shares gained 65% to $0.2887 in pre-market trading after gaining 12% on Monday. The company recently posted a narrower-than-expected quarterly loss.
Shares of TransCode Therapeutics, Inc. (NASDAQRNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday.
Gainers Fulcrum Therapeutics, Inc. (NASDAQFULC) shares jumped 42.8% to $5.60 after the FDA lifted clinical hold on the company’s FTX-6058 for sickle cell disease.
Gainers Biophytis S.A. (NASDAQBPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's main product.
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 0.25% on Monday. The Dow traded up 0.25% to 34,596.04 while the NASDAQ rose 0.92% to 14,243.64. The S&P 500, also rose, gaining, 0.43% to 4,524.74.
ProMIS Neurosciences Inc. (NASDAQPMN) shares skyrocketed Monday after the company presented preclinical data supporting the potential therapeutic advantage of its lead candidate for Alzheimer's disease (AD), PMN310, and additional studies that further characterize a computationally-derived AD vaccine <
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Monday. The Dow traded up 0.19% to 34,574.01 while the NASDAQ rose 0.71% to 14,214.50. The S&P 500, also rose, gaining, 0.31% to 4,519.25.
Gainers ProMIS Neurosciences, Inc. (NASDAQPMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived antibody and vaccine from Alzheimer's pipeline.
U.S. stocks traded slightly higher this morning, with the Dow Jones moving higher by around 20 points on Monday. Following the market opening Monday, the Dow traded up 0.06% to 34,529.57 while the NASDAQ rose 0.25% to 14,149.04. The S&P 500, also rose, gaining, 0.06% to 4,508.18.
Gainers Mobilicom Limited (NASDAQMOB) shares jumped 81.3% to $2.7187 after the company announced it received a commercial scale purchase order from Teledyne-FLIR for the production of drones for the U.S. Department of Defense.
